- Home
- SWIM vs ABUS Comparison
SWIM vs ABUS Comparison
Compare SWIM & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWIM
- ABUS
- Stock Information
- Founded
- SWIM 1956
- ABUS N/A
- Country
- SWIM United States
- ABUS United States
- Employees
- SWIM N/A
- ABUS N/A
- Industry
- SWIM Plastic Products
- ABUS Biotechnology: Pharmaceutical Preparations
- Sector
- SWIM Industrials
- ABUS Health Care
- Exchange
- SWIM Nasdaq
- ABUS Nasdaq
- Market Cap
- SWIM 833.7M
- ABUS 636.2M
- IPO Year
- SWIM 2021
- ABUS N/A
- Fundamental
- Price
- SWIM $6.84
- ABUS $3.32
- Analyst Decision
- SWIM Hold
- ABUS Strong Buy
- Analyst Count
- SWIM 5
- ABUS 4
- Target Price
- SWIM $5.98
- ABUS $5.50
- AVG Volume (30 Days)
- SWIM 844.6K
- ABUS 1.1M
- Earning Date
- SWIM 03-04-2025
- ABUS 05-01-2025
- Dividend Yield
- SWIM N/A
- ABUS N/A
- EPS Growth
- SWIM N/A
- ABUS N/A
- EPS
- SWIM N/A
- ABUS N/A
- Revenue
- SWIM $508,520,000.00
- ABUS $6,742,000.00
- Revenue This Year
- SWIM $6.10
- ABUS N/A
- Revenue Next Year
- SWIM $5.44
- ABUS N/A
- P/E Ratio
- SWIM N/A
- ABUS N/A
- Revenue Growth
- SWIM N/A
- ABUS N/A
- 52 Week Low
- SWIM $2.38
- ABUS $2.30
- 52 Week High
- SWIM $8.41
- ABUS $4.72
- Technical
- Relative Strength Index (RSI)
- SWIM 51.39
- ABUS 49.63
- Support Level
- SWIM $6.85
- ABUS $3.32
- Resistance Level
- SWIM $7.40
- ABUS $3.55
- Average True Range (ATR)
- SWIM 0.49
- ABUS 0.20
- MACD
- SWIM 0.10
- ABUS -0.02
- Stochastic Oscillator
- SWIM 66.28
- ABUS 44.12
About SWIM Latham Group Inc.
Latham Group Inc is a designer, manufacturer, and marketer of in-ground residential swimming pools, liners, and covers in North America, Australia, and New Zealand. It derives a majority of its revenue from the United States.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.